Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myeloproliferative Disorders × neratinib × 30 days × Clear all

Sponsor

Conditions

Neoplasm Metastasis 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Malignant Female Reproductive System Neoplasm 1 Hemangiosarcoma 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1

Interventions

Specimen Handling 8 Biopsy 8 fludarabine 6 Azacitidine 6 venetoclax 5 Whole-Body Irradiation 4 Busulfan 4 ruxolitinib 3 decitabine and cedazuridine drug combination 3 Injections 3 Cytarabine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 fludarabine phosphate 2 Tacrolimus 2 Stem Cell Transplantation 2 Mycophenolic Acid 2 Liposomes 2 Granulocyte Colony-Stimulating Factor 2 Daunorubicin 2 Cyclosporins 2 Cyclophosphamide 2 CPX-351 2 ponatinib 1 pevonedistat 1 peginterferon alfa-2b 1 onvansertib 1 olutasidenib 1 nilotinib 1 luspatercept 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡